Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,667 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Combination Therapy placebo Clear all
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

NCT02573233
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

NCT01578278
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Bepotastine besilate formulation, Fluticasone propionate, Bepotastine besilate-fluticasone propionate, Placebo Comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain

NCT02837952
View directory record Official record
Conditions
Pain
Interventions
FDC IBU/APAP 250 mg/500 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 40 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 4, 2018 · Synced Sep 11, 2026, 10:38 AM EDT
Terminated Phase 3 Interventional Results available

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

NCT01244191
View directory record Official record
Conditions
Non Squamous, Non-small-cell Lung Cancer
Interventions
Tivantinib, Placebo, Erlotinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
111
States / cities
Tucson, Arizona • Los Angeles, California • Oxnard, California + 85 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 11, 2026, 10:38 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease

NCT01072526
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Euphrasia-based homeopathic therapy, Cyclosporin solution
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 11, 2026, 10:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

NCT07049055
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
El Segundo, California • Summit, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 11, 2026, 10:38 AM EDT
Not listed Phase 2 Interventional

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

NCT03669718
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
Interventions
ISA101b, Cemiplimab, Placebo
Biological · Drug · Other
Lead sponsor
ISA Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
10
States / cities
Duarte, California • San Diego, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Results available

Novel Combination Therapy for Osteoporosis in Men

NCT03994172
View directory record Official record
Conditions
Male Osteoporosis
Interventions
Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, placebo tablet, Calcium citrate tablet, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 85 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 2 Interventional

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

NCT00000912
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
44
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 11, 2026, 10:38 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

NCT00476996
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Leflunomide, Methotrexate, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
144
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD)

NCT04644003
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
STP1, Placebo
Drug
Lead sponsor
Stalicla SA
Industry
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

NCT02111577
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DCVAC/PCa, Placebo
Biological
Lead sponsor
SOTIO a.s.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
58
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy

NCT02538666
View directory record Official record
Conditions
Lung Cancer
Interventions
Nivolumab, Ipilimumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
28
States / cities
Sacramento, California • New Haven, Connecticut • Fort Myers, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Sep 11, 2026, 10:38 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

NCT07219602
View directory record Official record
Conditions
Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
Interventions
obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
32
States / cities
Sun City West, Arizona • La Jolla, California • Pomona, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

NCT04825288
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg, Phase II: XB2001 1000 mg, Phase II: Placebo
Biological
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
30
States / cities
Tucson, Arizona • Burbank, California • Cerritos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 11, 2026, 10:38 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Treatment of Keratoconus Using Collagen Cross-Linking

NCT00841386
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin-5-phosphate, Sham cross-linking
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
16 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Amherst, New York • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2009 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Results available

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03227445
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA placebo DPI, DISKUS placebo DPI, HandiHaler placebo DPI, Inhaler preference questionnaires
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Orlando, Florida • Natchitoches, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 11, 2026, 10:38 AM EDT
Not listed Phase 2 Interventional

Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease

NCT01560754
View directory record Official record
Conditions
Parkinson's Disease
Interventions
nicotine transdermal patch
Drug
Lead sponsor
James BOYD MD
Other
Eligibility
30 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Los Angeles, California • Sunnyvale, California • Honolulu, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Sep 11, 2026, 10:38 AM EDT
Terminated Phase 3 Interventional

Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes

NCT00690456
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rimonabant, Placebo (for Rimonabant), Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea

NCT03892772
View directory record Official record
Conditions
Sleep Apnea
Interventions
SAS0421a, SAS0421b, SAS0421c, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 1 Interventional

Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452

NCT00006495
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), HIV-1 Immunogen
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
9
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses

NCT03752307
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Isoxsuprine Hydrochloride, Placebo, Corticosteroid
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 11, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects

NCT00903409
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Simvastatin + Lovaza® (omega-3-acid ethyl esters)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
40
States / cities
Mobile, Alabama • Encinitas, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Sep 11, 2026, 10:38 AM EDT